MilliporeSigma
  • Controlled Drug Delivery by Polylactide Stereocomplex Micelle for Cervical Cancer Chemotherapy.

Controlled Drug Delivery by Polylactide Stereocomplex Micelle for Cervical Cancer Chemotherapy.

Frontiers in pharmacology (2018-08-30)
Kai Niu, Yunming Yao, Ming Xiu, Chunjie Guo, Yuanyuan Ge, Jianmeng Wang
ABSTRACT

A stable doxorubicin (DOX)-loaded stereocomplex micelle drug delivery system was developed via the stereocomplex interaction between enantiomeric 4-armed poly(ethylene glycol)-poly(D-lactide) and poly(ethylene glycol)-poly(L-lactide) to realize control drug release and improve tumor cell uptake for efficient cervical carcinoma therapy. All these DOX-loaded micelles including poly(D-lactide)-based micelle (PDM/DOX), poly(L-lactide)-based micelle (PLM/DOX), and stereocomplex micelle (SCM/DOX) exhibited appropriate sizes of ∼100 nm for the enhanced permeability and retention (EPR) effect. In addition, compared to PDM/DOX and PLM/DOX, SCM/DOX exhibited the slowest DOX releaser, highest tumor cell uptake and the most efficient tumor cell suppression in vitro. Moreover, the excellent tumor inhibiting rates of the DOX-loaded micelles, especially SCM/DOX, were verified in the U14 cervical carcinoma mouse model. Increased tumorous apoptosis and necrosis areas were observed in the DOX-loaded micelles treatment groups, especially the SCM/DOX group. In addition, all these DOX-loaded micelles obviously alleviated the systemic toxicity of DOX. As a result, SCM can be a promising drug delivery system for the future therapy of cervical carcinoma.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2-Phenylindole, technical grade, 95%
Sigma-Aldrich
Poly(L-lactide) dimethacrylate, average Mn 10,000
Sigma-Aldrich
Poly(L-lactide) dimethacrylate, average Mn 5,000